



S.S. FINAL

Thursday, 6 November, 2014

Bridge 5 Room, Crowne Plaza Hotel, Melbourne, Australia

GCIG CERVIX CANCER BRAINSTORMING DAY

PROGRAM

Chair: Satoru Sagae (Cx Ca Comm. Chair & JGOG)

Co-Chair: Brad Monk (Cx Ca Comm. Co-Chair & GOG)

Core Scientific Committee: Eric Pujade-Lauraine (GCIG Chair & GINECO), Bill Small (GCIG Chair-elect & RTOG), Dave Gaffney (CCRN RT QA & RTOG), and Kailash Narayan (OUTBACK & ANZGOG).

Scientific and Planning Committee: Sang Ryu (TACO Chair & KGOG), Mary McCormack (INTERLACE Chair & MRC NCRI), Marie Plante (SHAPE Chair & NCIC CTG), Antonio Casado (EORTC GCG), Alexander Reuss (Stats & AGO-Ovar), and Adriana Chavez (Ops & GICOM).

Participants: GCIG member groups (2 representatives for each group)
Invited speakers / experts in the field
International guests/observers

Objectives:

- To validate control arms for present and future clinical trials involving cervix cancers;
- To identify national & international barriers for trials dedicated to cervix cancers;
- To summarize and prioritize key issues for research and agree new set of trial concepts to address the key issues.

8:00 – 8:30 **Registration**

8:30 – 8:35 **Welcome:** Satoru Sagae

8:35 – 8:45 **Objectives:** Brad Monk

8:50 – 9:00 **Surrogate Markers (as endpoints) --- A. Reuss**

<u>Session 1:</u>	<u>Local Disease Cervical Cancer-</u> Chair: S. Sagae	
9:00 – 9:25	Prognostic Groupings (speaker: Narayan)	
9:25 – 9:45	Should we include developing countries or do we need more than one study? Role of CCRN? (guest speaker: Kitchener)	
9:45 – 10:00	What is the control arm & endpoint? (speaker: B.H Nam)	
10:00 – 10:15	Is there a place for standard RT vs IMRT and IGBT in clinical trials? (speaker: A. Jhingran)	
10:15 – 10:30	Beverages	
<u>Session 2:</u>	<u>Metastatic Cervical Cancer-</u> Chair: B. Monk	
10:30 – 10:50	Can we do targeted therapy trials in developing countries? What are the barriers of shipping investigational agents across international lines? (guest speaker: Trimble)	
10:50 – 11:10	What is the control arm? Should it include bevacizumab? (speaker:Pujade)	
11:10 – 11:30	Is an assay directed trial feasible? (speaker: L.Mileshkin)	
11:30 – 11:50	What is the appropriate endpoint? Should we do phase II or phase III studies? (speaker: Chavez)	
11:50 – 12:00	Directions for afternoon Breakout Working Groups	
12:00 – 13:00	Lunch	
13:00 – 15:00	<u>Breakout Working Groups:</u>	
#1 - Topic:	<u>Translational Research:</u>	<u>Bridge 1 Room</u>
	[Chair: Casado – Co-Chair/rapporteur: McCormack – Ops rep: E.Aotani (& Choi) – Stats rep: T.Hamano]	
	Speakers & Discussion: E. Bern, S.Scholl, C.Doll.	
#2 - Topic:	<u>International Obstacles and Approaches:</u>	<u>Bridge 2 Room</u>
	[Chair: Ryu –Co-Chair/rapporteur: Small – Ops rep: A.Chavez – Stats rep: B.H.Nam]	
	<i>Trials in the developing world, International Needs, Partnerships, CCRN involvement and goals.</i>	
	Speakers & Discussion: S.Ryu, T.Trimble, H.Kitchener.	

- #3- Topic:** **Fertility sparing/preserving, node studies:** **Otway 2 Room**
[Chair: Plante – Co-Chair/rapporteur: E.Pujade-Lauraine – Ops rep:
J.Martyn – Stats rep: A.Reuss]
Speakers & Discussion: M.Plante, N.Abu-Rustum, F. Lecuru.
- 15:00 – 15:30** **Beverages**
- 15:30 – 16:00** **Breakout Working groups:** regroup --- summarize for report
- 16:00 – 16:30** **Plenary** – **REPORTS from Breakout Working groups (10 minutes each)**
- 16:30 – 17:15** **Plenary: Consensus Session: locally advanced disease** – **Chair: Sagae**
– Final discussion and consensus on 3 outcomes (priorities, concepts, goals)
- 17:15 – 18:00** **Plenary: Consensus Session: metastatic disease** – **Chairs: Monk**
– Final discussion and consensus on 3 outcomes (priorities, concepts, goals)
- 18:00** **Closure: Bill Small**
- 19:00** **GCIG DINNER**